Products
Dolasetron (Anzemet) is no longer on the market in many countries. It had been approved since 1999. The solution for injection was withdrawn in 2011 because of possible adverse effects (prolongation of the QT interval, cardiac arrhythmias), and later the tablets also went off the market.
Structure and properties
Dolasetron (C19H20N2O3, Mr = 324.4 g/mol) is present in the drug as dolasetron mesilate monohydrate.
Effects
Dolasetron (ATC A04AA04) is antiemetic and a sertotonin antagonist at 5-HT3 receptors.
Indication
Prevention of nausea and vomiting during cytotoxic chemotherapy.